These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29944945)

  • 21. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol.
    Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS
    J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Protein Conformation, Apparent Solubility, and Protein-Protein Interactions on the Rates and Mechanisms of Aggregation for an IgG1Monoclonal Antibody.
    Kalonia C; Toprani V; Toth R; Wahome N; Gabel I; Middaugh CR; Volkin DB
    J Phys Chem B; 2016 Jul; 120(29):7062-75. PubMed ID: 27380437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of infliximab solutions in different temperature and dilution conditions.
    Tokhadze N; Chennell P; Le Basle Y; Sautou V
    J Pharm Biomed Anal; 2018 Feb; 150():386-395. PubMed ID: 29287266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation.
    Narhi LO; Luo Q; Wypych J; Torosantucci R; Hawe A; Fujimori K; Nashed-Samuel Y; Jawa V; Joubert MK; Jiskoot W
    Pharm Res; 2017 Dec; 34(12):2817-2828. PubMed ID: 29110285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of Monoclonal Antibody Aggregation from Dilute toward Concentrated Conditions.
    Nicoud L; Jagielski J; Pfister D; Lazzari S; Massant J; Lattuada M; Morbidelli M
    J Phys Chem B; 2016 Apr; 120(13):3267-80. PubMed ID: 27007829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of varicella-zoster virus and herpes simplex virus IgG monoclonal antibodies.
    Hart J; Miller C; Tang X; Vafai A
    J Immunoassay Immunochem; 2009; 30(2):180-5. PubMed ID: 19330643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlating the Effects of Antimicrobial Preservatives on Conformational Stability, Aggregation Propensity, and Backbone Flexibility of an IgG1 mAb.
    Arora J; Joshi SB; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2017 Jun; 106(6):1508-1518. PubMed ID: 28212986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggregation of Recombinant Monoclonal Antibodies and Its Role in Potential Immunogenicity.
    Ignjatovic J; Svajger U; Ravnikar M; Molek P; Zadravec D; Paris A; Strukelj B
    Curr Pharm Biotechnol; 2018; 19(4):343-356. PubMed ID: 29874996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography-tandem mass spectrometry and size-exclusion chromatography-multi-angle light scattering.
    Legrand P; Dufaÿ S; Mignet N; Houzé P; Gahoual R
    Anal Bioanal Chem; 2023 Jan; 415(1):179-192. PubMed ID: 36449030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
    Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
    J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of Aggregation of Therapeutic Monoclonal Antibodies during Storage by Removal of Aggregation Precursors Using a Specific Adsorbent of Non-Native IgG Conformers.
    Senga Y; Honda S
    Bioconjug Chem; 2018 Oct; 29(10):3250-3261. PubMed ID: 30264991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics.
    Singla A; Bansal R; Joshi V; Rathore AS
    AAPS J; 2016 May; 18(3):689-702. PubMed ID: 26902302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
    Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
    Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice.
    Kijanka G; Bee JS; Korman SA; Wu Y; Roskos LK; Schenerman MA; Slütter B; Jiskoot W
    J Pharm Sci; 2018 Nov; 107(11):2847-2859. PubMed ID: 30003898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
    Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
    Trabik YA; Moenes EM; Al-Ghobashy MA; Nebsen M; Ayad MF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122359. PubMed ID: 32920338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid formulations for long-term storage of monoclonal IgGs.
    Mueller M; Loh MQ; Tee DH; Yang Y; Jungbauer A
    Appl Biochem Biotechnol; 2013 Feb; 169(4):1431-48. PubMed ID: 23315232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping the mAb Aggregation Propensity Using Self-Interaction Chromatography as a Screening Tool.
    Hedberg SHM; Lee D; Mishra Y; Haigh JM; Williams DR
    Anal Chem; 2018 Mar; 90(6):3878-3885. PubMed ID: 29446917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a (RP)UHPLC-UV-(HESI/Orbitrap)MS method for the identification and quantification of mixtures of intact therapeutical monoclonal antibodies using a monolithic column.
    Pérez-Robles R; Cuadros-Rodríguez L; Salmerón-García A; Navas N
    J Pharm Biomed Anal; 2018 Sep; 159():437-448. PubMed ID: 30071467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.